U.S. FDA approves first-line use of Boehringer Ingelheim's lung cancer drug

2026-02-27 - 12:02

Boehringer's Hernexeos was one of the 18 drugs selected ⁠so far for the FDA Commissioner's National Priority Voucher Program that allows speedy process and cuts the review time to ‌one to two months from the typical 10 to 12 months